Table 2.

Summary of Observational Studies on Dual Biologic Therapy with Denosumab Indicated for Treatment of Osteoporosis as a Comorbidity of Rheumatoid Arthritis.

Author (Year), Country Study Design Dual Therapy (n Patients) Control Arm (n Patients, if applicable) Primary Study Outcome Safety Outcomes of Dual Biologic TX
Curtis (2015), USA18 Retrospective Medicare database analysis Various bDMARDs+DEN (n=1354) Various bDMARDs+ zoledronic acid (n=4460) Hospitalized infection rate No increase of severe infections rate
Hasegawa (2016), Japan17 Retrospective case-control single-center study Various bDMARDs+DEN (n=40) Various bDMARDs (n=40) Radiographic progression (modified Sharp erosion score) No increase of infections and serious adverse events rate
Lau (2018), Canada19 Retrospective analysis of two rheumatology practices Various bDMARDs+DEN (n=102) Various bDMARDs (n=206) Serious or opportunistic infection rate Low rate of serious and opportunistic infections in both groups
Mirzaei (2021), Iran35 Retrospective case-control study Various bDMARDs+DEN (n=40) Various bDMARDs (n=44) Rate of infections Low rate of infections in both groups

bDMARD, biologic disease-modifying antirheumatic drug; DEN, denosumab; TX, treatment; USA, United States of America.

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2023 April; 14(2): e0007. ISSN: 2076-9172
Published online 2023 April 30. doi: 10.5041/RMMJ.10494